Articles related to COMBINATION THERAPY

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

This phase 2 study underscores the challenges in enhancing therapeutic outcomes in metastatic castration-resistant prostate cancer with AZD4635 combined with immunotherapy, indicating a minimal PSA response among treated patients.

In managing acute decompensated heart failure, optimizing loop diuretic therapy is pivotal; initial aggressive dosing tailored to urinary outputs can significantly improve patient outcomes.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.